Trans-Myocardial Blood Interleukin-6 Levels Relate to Intracoronary Imaging-Defined Features of Plaque Vulnerability and Predict Procedure-Induced Myocardial Infarction

Bambrough, Paul; Peverelli, Marta; Brown, Adam; Giblett, Joel P.; Bennett, Martin R.; West, N E J; Hoole, Stephen P.

doi:10.1016/j.carrev.2021.10.006

Cited by 6 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another large-scale study conducted by Ferencik et al demonstrated that IL-6 was related to Coronary Artery Disease Reporting and Data System (CAD-RADS) categories and the degree of coronary stenosis in CCTA, being also predictive of major adverse cardiovascular events [95]. Another interesting observation was made by Bambrough et al, who identified a local biomarker signature, the IL-6 trans-myocardial gradient, prior to percutaneous coronary intervention as an important indicator of plaque burden and minimal lumen area [96]. In this direction, it has been previously reported that aspirated serum in culprit coronary arteries of patients with acute myocardial infarction had significantly higher concentrations of IL-6 compared to peripheral blood early in the course of the event [97].…”

Section: Il-6mentioning

confidence: 96%

The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches

Tsioufis¹,

Theofilis²,

Tsioufis³

et al. 2022

IJMS

View full text Add to dashboard Cite

Coronary atherosclerosis is a chronic pathological process that involves inflammation together with endothelial dysfunction and lipoprotein dysregulation. Experimental studies during the past decades have established the role of inflammatory cytokines in coronary artery disease, namely interleukins (ILs), tumor necrosis factor (TNF)-α, interferon-γ, and chemokines. Moreover, their value as biomarkers in disease development and progression further enhance the validity of this interaction. Recently, cytokine-targeted treatment approaches have emerged as potential tools in the management of atherosclerotic disease. IL-1β, based on the results of the CANTOS trial, remains the most validated option in reducing the residual cardiovascular risk. Along the same line, colchicine was also proven efficacious in preventing major adverse cardiovascular events in large clinical trials of patients with acute and chronic coronary syndrome. Other commercially available agents targeting IL-6 (tocilizumab), TNF-α (etanercept, adalimumab, infliximab), or IL-1 receptor antagonist (anakinra) have mostly been assessed in the setting of other inflammatory diseases and further testing in atherosclerosis is required. In the future, potential targeting of the NLRP3 inflammasome, anti-inflammatory IL-10, or atherogenic chemokines could represent appealing options, provided that patient safety is proven to be of no concern.

show abstract

Section: Il-6mentioning

confidence: 96%

The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches

Tsioufis¹,

Theofilis²,

Tsioufis³

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…In addition, the progression of atherosclerotic cardiovascular disease is influenced by systemic vascular inflammation, which contributes to multiple maladaptive processes [ 15 ]. Interleukin-6 (IL-6), a pro-inflammatory cytokine, has been proposed as a potential predictor of coronary artery disease (CAD) severity and has been associated with plaque burden, as assessed by intracoronary imaging [ 16 , 17 ]. Furthermore, evidence suggests that the activation of the inflammatory pathway is crucial for ceramide biosynthesis [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Ceramides and pro-inflammatory cytokines for the prediction of acute coronary syndrome: a multi-marker approach

Liang,

Li,

Zhang

et al. 2024

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background There is a growing body of evidence supporting the significant involvement of both ceramides and pro-inflammatory cytokines in the occurrence and progression of acute coronary syndrome (ACS). Methods This study encompassed 216 participants whose laboratory variables were analysed using standardised procedures. Parameters included baseline serum lipid markers, comprising total cholesterol, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol, triglycerides (TGs), lipoprotein(a) (LPa), fasting blood glucose, B-natriuretic peptide and hypersensitive C-reactive protein. Liquid chromatography-tandem mass spectrometry measured the concentrations of plasma ceramides. Enzyme-linked immunosorbent assay quantified tumour necrosis factor-α (TNF-α), interleukin 6 (IL6) and IL8. The correlation between ceramides and inflammatory factors was determined through Pearson’s correlation coefficient. Receiver operating characteristic (ROC) curve analysis and multivariate logistic regression evaluated the diagnostic potential of models incorporating traditional risk factors, ceramides and pro-inflammatory cytokines in ACS detection. Results Among the 216 participants, 138 (63.89%) were diagnosed with ACS. Univariate logistic regression analysis identified significant independent predictors of ACS, including age, gender, history of diabetes, smoking history, TGs, TNF-α, IL-6, ceramide (d18:1/16:0), ceramide (d18:1/18:0), ceramide (d18:1/24:0), ceramide (d18:1/20:0) and ceramide (d18:1/22:0). Multivariate logistic regression analysis revealed significant associations between gender, diabetes mellitus history, smoking history, LPa, IL-6, ceramide (d18:1/16:0) and ACS. Receiver operating characteristic analysis indicated that model 4, which integrated traditional risk factors, IL-6 and ceramide (d18:1/16:0), achieved the highest area under the curve (AUC) of 0.827 (95% CI 0.770–0.884), compared with model 3 (traditional risk factors and ceramide [d18:1/16:0]) with an AUC of 0.782 (95% CI 0.720–0.845) and model 2 (traditional risk factors and IL-6), with an AUC of 0.785 (95% CI 0.723–0.846) in ACS detection. Conclusions In summary, incorporating the simultaneous measurement of traditional risk factors, pro-inflammatory cytokine IL-6 and ceramide (d18:1/16:0) can improve the diagnostic accuracy of ACS.

show abstract

“…Methods used to address this have included ex vivo sampling of atherosclerotic plaques (15,16) and coronary thrombi (17,18) or use of aspiration or guide catheters to sample blood directly from the coronary artery (19)(20)(21). Samples collected from the coronary sinus, a venous reservoir receiving drainage from the majority of the coronary circulation, have been compared to blood sampled from the coronary ostium to identify transmyocardial gradients of certain proteins, potentially reflecting coronary disease status more accurately than analysis solely of systemic proteins sampled remotely (22).…”

Section: Introductionmentioning

confidence: 99%

Identification of a specific inflammatory protein biosignature in coronary and peripheral blood associated with increased risk of future cardiovascular events

Proudfoot¹,

Gigante

West

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background and rationale As an adjunct to coronary intervention, the Liquid Biopsy System (LBS, PlaqueTec, UK) enables accurate intracoronary blood sampling as previously documented. Here we investigate variation between local coronary and remote (peripheral) levels of certain proteins and how this might relate to cardiovascular risk assessment. Methods and Results Coronary artery blood samples were collected from 12 patients with obstructive coronary plaques before percutaneous coronary intervention (PCI), using the LBS. Peripheral blood samples were also collected, before and after PCI. Protein levels in coronary and peripheral plasma samples were analysed by proximity extension assay (PEA, Olink) and results were compared with blood samples from healthy controls and reference cohorts. Before PCI, 10/12 patients showed elevations in hepatocyte growth factor (HGF), pappalysin-1 (PAPPA) and spondin-1 (SPON1), in some cases >10-fold greater in coronary compared with peripheral samples. Following PCI, involving iatrogenic plaque rupture prior to stenting, peripheral levels of these proteins were elevated to a similar degree as coronary levels. In the other 2 patients, peripheral elevations for HGF, PAPPA and SPON1 (all >90th centile) were observed prior to PCI. This protein biosignature was absent in healthy controls but was detected in a minority of individuals in reference cohorts and associated with the occurrence of major adverse cardiovascular events (MACE) and mortality. Conclusions From investigation of coronary and peripheral blood samples, we identified a molecular signature, which when present in peripheral blood appears to portend worse outcomes. Measurement of these proteins could therefore aid identification of individuals at high risk of cardiovascular events.

show abstract

Trans-Myocardial Blood Interleukin-6 Levels Relate to Intracoronary Imaging-Defined Features of Plaque Vulnerability and Predict Procedure-Induced Myocardial Infarction

Cited by 6 publications

References 37 publications

The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches

The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches

Ceramides and pro-inflammatory cytokines for the prediction of acute coronary syndrome: a multi-marker approach

Identification of a specific inflammatory protein biosignature in coronary and peripheral blood associated with increased risk of future cardiovascular events

Contact Info

Product

Resources

About